These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15251260)

  • 21. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
    Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
    Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats.
    Aguiar LM; Nobre HV; Macêdo DS; Oliveira AA; Freitas RM; Vasconcelos SM; Cunha GM; Sousa FC; Viana GS
    Pharmacol Biochem Behav; 2006 Jul; 84(3):415-9. PubMed ID: 16844208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson's disease.
    Anastasia A; de Erausquin GA; Wojnacki J; Mascó DH
    J Neurochem; 2007 Nov; 103(4):1542-52. PubMed ID: 17854351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early pubertal female rats are more resistant than males to 6-hydroxydopamine neurotoxicity and behavioural deficits: a possible role for trophic factors.
    Pienaar IS; Schallert T; Russell VA; Kellaway LA; Carr JA; Daniels WM
    Restor Neurol Neurosci; 2007; 25(5-6):513-26. PubMed ID: 18334769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity.
    Dluzen DE; McDermott JL
    Ann N Y Acad Sci; 2004 Oct; 1025():205-20. PubMed ID: 15542719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease.
    Zbarsky V; Datla KP; Parkar S; Rai DK; Aruoma OI; Dexter DT
    Free Radic Res; 2005 Oct; 39(10):1119-25. PubMed ID: 16298737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease.
    Falk T; Zhang S; Sherman SJ
    Neurosci Lett; 2009 Jul; 458(2):49-52. PubMed ID: 19442875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles.
    Huang R; Han L; Li J; Ren F; Ke W; Jiang C; Pei Y
    J Gene Med; 2009 Sep; 11(9):754-63. PubMed ID: 19554623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model.
    Quik M; O'Neill M; Perez XA
    Trends Pharmacol Sci; 2007 May; 28(5):229-35. PubMed ID: 17412429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reductions in spontaneous locomotor activity in aged male, but not female, rats in a model of early Parkinson's disease.
    Cass WA; Peters LE; Smith MP
    Brain Res; 2005 Feb; 1034(1-2):153-61. PubMed ID: 15713267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of age and gender on cytokine expression in a murine model of Parkinson's disease.
    Ciesielska A; Joniec I; Kurkowska-Jastrzebska I; Przybyłkowski A; Gromadzka G; Członkowska A; Członkowski A
    Neuroimmunomodulation; 2007; 14(5):255-65. PubMed ID: 18196934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis.
    Kadota T; Shingo T; Yasuhara T; Tajiri N; Kondo A; Morimoto T; Yuan WJ; Wang F; Baba T; Tokunaga K; Miyoshi Y; Date I
    Brain Res; 2009 Feb; 1254():120-7. PubMed ID: 19101524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway.
    Guo S; Yan J; Yang T; Yang X; Bezard E; Zhao B
    Biol Psychiatry; 2007 Dec; 62(12):1353-62. PubMed ID: 17624318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications for estrogens in Parkinson's disease: an epidemiological approach.
    Ragonese P; D'Amelio M; Savettieri G
    Ann N Y Acad Sci; 2006 Nov; 1089():373-82. PubMed ID: 17261781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model.
    Yasuhara T; Shingo T; Muraoka K; wen Ji Y; Kameda M; Takeuchi A; Yano A; Nishio S; Matsui T; Miyoshi Y; Hamada H; Date I
    Brain Res; 2005 Mar; 1038(1):1-10. PubMed ID: 15748867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system.
    Liu B; Dluzen DE
    Synapse; 2006 Oct; 60(5):354-61. PubMed ID: 16838362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review.
    Sherwin BB; Henry JF
    Front Neuroendocrinol; 2008 Jan; 29(1):88-113. PubMed ID: 17980408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.